861 results
Search Results
2. Paper of the Month 2023 Winners
- Published
- 2023
- Full Text
- View/download PDF
3. 202-OR: Basal Insulin Digital Titration App vs. Enhanced Paper Titration Tool: A Randomized Control Study
- Author
-
Arati Kanchi, Addie L. Fortmann, Alessandra Bastian, Linda Parks, Michael S. Greenfield, Athena Philis-Tsimikas, Ricardo Abad, Tong Sheng, and Mark A. Clements
- Subjects
medicine.medical_specialty ,Intention-to-treat analysis ,business.industry ,Endocrinology, Diabetes and Metabolism ,Insulin ,medicine.medical_treatment ,Basal insulin ,Type 2 diabetes ,medicine.disease ,Insulin dose ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,Diabetes mellitus ,Cohort ,Internal Medicine ,medicine ,business - Abstract
Self-adjusting insulin is challenging for people with type 2 diabetes (PWT2D). Mobile health technologies (mHealth) can help PWT2D track blood glucose more easily, but it remains unclear whether an mHealth-enabled digital therapeutic tool can effectively support basal insulin (BI) titration in a large multispecialty health care setting. We randomized 242 PWT2D on BI (baseline HbA1c 7.5% - 12.5%) to use either an app-based self-titration tool [Mobile Insulin Dosing System (MIDS)] or an enhanced paper titration tool based on a stepped algorithm with diabetes educator support (control) for 16 weeks. Cohort characteristics for the intent to treat sample (MIDS n = 117; control n = 120) were: median age 61 years [IQR: 53 - 69], 41.7% female, 75.9% non-Hispanic White, 11.4% new to insulin, median duration of diabetes 11 years [IQR: 7 - 18], and median baseline HbA1c of 8.7% [IQR: 8.0 - 9.6]. Improvements in HbA1c (-1.3% [IQR: -2.2 - -.5] and -1.2% [IQR: -1.9 - -.5]; both Ps < .05) with increased median insulin dose (+8 IU [IQR: 2 - 22] and +10 IU [IQR: 2 - 25.5]; both Ps < .05) and no change in hypoglycemia were observed at 16 weeks in both the MIDS and control groups, respectively. No differences in HbA1c (P = .48) or insulin dose change (P = .34) were observed between the groups. Among SMBG readings recorded during the study, the mean proportion of readings between 70-180 mg/dL (76.8% ± 22.0; 70.0% ± 26.7; p250 mg/dL (4.9% ± 9.2; 9.2% ± 18.4; p Disclosure A. Philis-Tsimikas: Advisory Panel; Self; Lilly Diabetes, Medtronic, Novo Nordisk A/S, Sanofi. Employee; Spouse/Partner; Ionis Pharmaceuticals, Inc. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Dexcom, Inc., Lilly Diabetes, Medtronic, Novo Nordisk A/S, Sanofi. A.L. Fortmann: None. A. Bastian: None. A. Kanchi: Employee; Self; Glooko, Inc. Stock/Shareholder; Self; Glooko, Inc. R. Abad: Employee; Self; Glooko, Inc. T. Sheng: Employee; Self; Glooko, Inc. L. Parks: Employee; Self; Glooko, Inc. M. Greenfield: Consultant; Self; Glooko, Inc. M.A. Clements: Consultant; Self; Glooko, Inc. Other Relationship; Self; Glooko, Inc.
- Published
- 2020
4. 202-OR: Basal Insulin Digital Titration App vs. Enhanced Paper Titration Tool: A Randomized Control Study
- Author
-
PHILIS-TSIMIKAS, ATHENA, primary, FORTMANN, ADDIE L., additional, BASTIAN, ALESSANDRA, additional, KANCHI, ARATI, additional, ABAD, RICARDO, additional, SHENG, TONG, additional, PARKS, LINDA, additional, GREENFIELD, MICHAEL, additional, and CLEMENTS, MARK A., additional
- Published
- 2020
- Full Text
- View/download PDF
5. Expanding Treatment Options for Youth With Type 2 Diabetes: Current Problems and Proposed Solutions: A White Paper From the NICHD Diabetes Working Group.
- Author
-
Tamborlane WV, Haymond MW, Dunger D, Shankar R, Gubitosi-Klug R, Bethin K, Karres J, Tomasi P, Libman I, Hale PH, Portman R, Klingensmith G, Reed M, Blumer J, and Giacoia G
- Published
- 2016
- Full Text
- View/download PDF
6. PAPER trails.
- Author
-
Tsai, Allison
- Subjects
MANAGEMENT of medical records ,RECORDS management ,COST control ,SCANNING systems ,INFORMATION storage & retrieval systems - Abstract
The article focuses on organizing medical and insurance documents which saves time, money, and stress. It recommends separating documents into current documents and reference documents. The important documents that must be kept include explanation of benefits, medical bills, labor orders, and pharmacy receipts. Storing scanned medical documents and records in a folder on one's computer is also recommended.
- Published
- 2018
7. Expanding Treatment Options for Youth With Type 2 Diabetes: Current Problems and Proposed Solutions
- Author
-
Janina Karres, William V. Tamborlane, Paula H. Hale, Kathleen E. Bethin, Rose Gubitosi-Klug, Jeffrey L. Blumer, George P. Giacoia, Georgeanna J. Klingensmith, Paolo Tomasi, Morey W. Haymond, Michael D. Reed, R. Ravi Shankar, Ingrid Libman, Ronald J. Portman, and David B. Dunger
- Subjects
Advanced and Specialized Nursing ,Type 1 diabetes ,Pediatrics ,medicine.medical_specialty ,business.industry ,Endocrinology, Diabetes and Metabolism ,MEDLINE ,Alternative medicine ,030209 endocrinology & metabolism ,Disease ,Type 2 diabetes ,medicine.disease ,Natural history ,03 medical and health sciences ,0302 clinical medicine ,White paper ,Family medicine ,Diabetes mellitus ,Internal Medicine ,Medicine ,030212 general & internal medicine ,business - Abstract
The Best Pharmaceuticals for Children Act of 2002 mandated that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) carries out critical reviews of the gaps in knowledge and unmet needs regarding safe and effective pharmacologic treatment of infants, children, and adolescents in a broad range of disease areas. In 2012, NICHD selected diabetes mellitus as one of the pediatric disorders for review. Dr. William V. Tamborlane was named chair, and Dr. Linda DiMeglio, vice-chair, of the Diabetes Working Group. Together with Dr. George Giacoia of NICHD, they assembled a distinguished group of medical experts in childhood diabetes, including clinicians/clinical investigators from leading academic centers and from industry and representatives from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), to carry out this review. It is very important to note that the views expressed in this article, as well as in other reports from the Diabetes Working Group, are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the FDA or EMA or any of the organizations or pharmaceutical companies represented in our working group. As shown in Supplementary Table 1, the large Diabetes Working Group was divided into five committees: Type 1 Diabetes (T1D): Therapeutics, Type 2 Diabetes (T2D): Therapeutics, T1D: Natural History and Biomarkers, T2D: Natural History and Biomarkers, and Diabetes Pharmacology. The consensus of the T2D Therapeutics Committee was that its efforts should address the crisis in care that clinicians face in treating this disorder in adolescents. Despite a plethora of new drug classes and new agents within each class that have been approved for use in adults with T2D, in …
- Published
- 2016
8. Response to Comment on Garvey et al. Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial. Diabetes Care 2024;47:562–570.
- Author
-
Garvey, W. Timothy and Cohen, Robert M.
- Subjects
GLUCAGON-like peptide 1 ,TYPE 2 diabetes ,GLYCEMIC control ,DIGESTIVE system diseases ,DIABETES complications - Abstract
The document is a response to a comment on a paper analyzing baseline factors associated with glycemic outcomes in patients with type 2 diabetes. The authors of the response acknowledge the observations made in the comment letter regarding patient attributes that predict differential glycemic responses. They discuss the findings of their own study, which explored various baseline characteristics and identified treatment group, age, HbA1c, and fasting glucose as significant factors in predicting glycemic outcomes. The authors also express agreement with the idea of individualized selection of diabetes medications based on clinical characteristics and emphasize the need for longer-term studies to assess factors that predict differential responsiveness. They clarify a point regarding the association between insulin secretion and the effectiveness of the medication liraglutide. The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
9. Takeout at Home.
- Author
-
Webb, Robyn
- Subjects
COOKING ,MANGO ,CHICKEN as food - Abstract
Two Asian-inspired recipes are presented including Rice Paper Roll-Ups and Mango Chicken Stir-Fry.
- Published
- 2016
10. The Gut Microbiota and Diabetes: Clarity on an Emerging Topic and Introduction to a New Partnership and Journal Feature.
- Author
-
D'Alessio, David A., Kahn, Steven E., and Mulder, Hindrik
- Subjects
TYPE 1 diabetes ,TYPE 2 diabetes ,PEOPLE with diabetes ,GUT microbiome ,MEDICAL sciences - Abstract
This article discusses the relationship between the gut microbiota and type 2 diabetes. While research has shown that there are differences in the gut microbiota between individuals with and without diabetes, there is still much to be understood about this complex area of biology. The article highlights the interest in this topic and its potential impact on clinical medicine. The authors also mention a partnership with the Novo Nordisk Foundation to fund further research and expert forums on key topics related to diabetes. The article concludes by stating that the goal of these initiatives is to advance the understanding and treatment of diabetes. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
11. Statement of Retraction. Iria Nieto-Vázquez, Sonia Fernández-Veledo, Cristina de Alvaro, and Margarita Lorenzo. Dual Role of Interleukin-6 in Regulating Insulin Sensitivity in Murine Skeletal Muscle. Diabetes 2008;57:3211-3221. https://doi.org/10.2337/db07-1062.
- Author
-
American Diabetes Association
- Subjects
INSULIN resistance ,SKELETAL muscle ,INTERLEUKIN-6 ,DIABETES ,MARGARITAS - Abstract
The article discusses that the representative immunoblot images in the above-cited paper may have been duplicated, authors Iria Nieto-Vázquez and Sonia Fernández-Veledo have decided to voluntarily retract the article.
- Published
- 2020
- Full Text
- View/download PDF
12. Diabetic Wound Keratinocytes Induce Macrophage JMJD3-Mediated Nlrp3 Expression via IL-1R Signaling.
- Author
-
Wolf, Sonya J., Audu, Christopher O., Moon, Jadie Y., Joshi, Amrita D., Melvin, William J., Barrett, Emily C., Mangum, Kevin, de Jimenez, Gabriela Saldana, Rocco, Sabrina, Buckley, Sam, Ahmed, Zara, Wasikowski, Rachael, Kahlenberg, J. Michelle, Tsoi, Lam C., Gudjonsson, Johann E., and Gallagher, Katherine A.
- Subjects
MYELOID cells ,GENE expression ,WOUND healing ,NLRP3 protein ,TISSUE wounds - Abstract
Macrophage (Mφ) plasticity is critical for normal wound repair; however, in type 2 diabetic wounds, Mφs persist in a low-grade inflammatory state that prevents the resolution of wound inflammation. Increased NLRP3 inflammasome activity has been shown in diabetic wound Mφs; however, the molecular mechanisms regulating NLRP3 expression and activity are unclear. Here, we identified that diabetic wound keratinocytes induce Nlrp3 gene expression in wound Mφs through IL-1 receptor–mediated signaling, resulting in enhanced inflammasome activation in the presence of pathogen-associated molecular patterns and damage-associated molecular patterns. We found that IL-1α is increased in human and murine wound diabetic keratinocytes compared with nondiabetic controls and directly induces Mφ Nlrp3 expression through IL-1 receptor signaling. Mechanistically, we report that the histone demethylase, JMJD3, is increased in wound Mφs late post-injury and is induced by IL-1α from diabetic wound keratinocytes, resulting in Nlrp3 transcriptional activation through an H3K27me3-mediated mechanism. Using genetically engineered mice deficient in JMJD3 in myeloid cells (Jmjd3
f/f lyz2Cre+ ), we demonstrate that JMJD3 controls Mφ-mediated Nlrp3 expression during diabetic wound healing. Thus, our data suggest a role for keratinocyte-mediated IL-1α/IL-1R signaling in driving enhanced NLRP3 inflammasome activity in wound Mφs. These data also highlight the importance of cell cross-talk in wound tissues and identify JMJD3 and the IL-1R signaling cascade as important upstream therapeutic targets for Mφ NLRP3 inflammasome hyperactivity in nonhealing diabetic wounds. Article Highlights: The molecular mechanism regulating macrophage (Mφ) NLRP3 inflammasome activity in diabetic wounds remains unclear. Diabetic wound keratinocytes induce Nlrp3 gene expression and enhance inflammasome activation in wound Mφs through IL-1 receptor–mediated signaling. IL-1α is increased in human and murine wound diabetic keratinocytes compared with nondiabetic controls and directly induces Mφ Nlrp3 expression via histone demethylase, JMJD3. JMJD3 controls Mφ-mediated Nlrp3 expression during wound healing. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
13. Complement Factor C1q Mediates Vascular Endothelial Dysfunction in STZ-Induced Diabetic Mice.
- Author
-
Mao, Aiqin, Li, Zicheng, Shi, Xiaoming, Zhang, Ka, Kan, Hao, Geng, Li, and He, Dongxu
- Subjects
VASCULAR endothelial cells ,DIABETES complications ,ENDOTHELIUM diseases ,REACTIVE oxygen species ,MUSCLE cells - Abstract
Diabetes is a significant global public health issue with implications for vascular endothelial cells (ECs) dysfunction and the subsequent development and advancement of diabetes complications. This study aims to compare the cellular and molecular properties of the aorta in normal and streptozotocin (STZ)-induced diabetic mice, with a focus on elucidating potential mechanism underlying EC dysfunction. Here, we performed a single-cell RNA sequencing survey of 32,573 cells from the aorta of normal and STZ-induced diabetic mice. We found a compendium of 10 distinct cell types, mainly ECs, smooth muscle cells, fibroblast, pericyte, immune cells, and stromal cells. As the diabetes condition progressed, we observed a subpopulation of aortic ECs that exhibited significantly elevated expression of complement (C) molecule C1qa compared with their healthy counterparts. This increased expression of C1qa was found to induce reactive oxygen species (ROS) production, facilitate EC migration and increased permeability, and impair the vasodilation within the aortic segment of mice. Furthermore, AAV-Tie2-shRNA-C1qa was administered into diabetic mice by tail vein injection, showing that inhibition of C1qa in the endothelium led to a reduction in ROS production, decreased vascular permeability, and improved vasodilation. Collectively, these findings highlight the crucial involvement of C1qa in endothelial dysfunction associated with diabetes. Article Highlights: The molecular mechanisms and cellular heterogeneity of C1q in endothelial cells, which regulate vascular function, remain unclear. C1q is involved in the regulation of vascular function. C1q in vascular endothelial cells can regulate vascular function, including permeability, immunity, and diastolic function. C1q represents a promising therapeutic target for the treatment of endothelial dysfunction associated with diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Nutritional Status, Dietary Intake, and Nutrition-Related Interventions Among Older Adults With Type 1 Diabetes: A Systematic Review and Call for More Evidence Toward Clinical Guidelines.
- Author
-
Cristello Sarteau, Angelica, Ercolino, Gabriella, Muthukkumar, Rashmi, Fruik, Angela, Mayer-Davis, Elizabeth J., and Kahkoska, Anna R.
- Subjects
TYPE 1 diabetes ,FOOD habits ,TYPE 2 diabetes ,DIETARY patterns ,NUTRITIONAL requirements - Abstract
There is an emerging population of older adults (≥65 years) living with type 1 diabetes. Optimizing health through nutrition during this life stage is challenged by multiple and ongoing changes in diabetes management, comorbidities, and lifestyle factors. There is a need to understand nutritional status, dietary intake, and nutrition-related interventions that may maximize well-being throughout the life span in type 1 diabetes, in addition to nutrition recommendations from clinical guidelines and consensus reports. Three reviewers used Cochrane guidelines to screen original research (January 1993–2023) and guidelines (2012–2023) in two databases (MEDLINE and CENTRAL) to characterize nutrition evidence in this population. We found limited original research explicitly focused on nutrition and diet in adults ≥65 years of age with type 1 diabetes (six experimental studies, five observational studies) and meta-analyses/reviews (one scoping review), since in the majority of analyses individuals ≥65 years of age were combined with those age ≥18 years, with diverse diabetes durations, and also individuals with type 1 and type 2 diabetes were combined. Further, existing clinical guidelines (n = 10) lacked specificity and evidence to guide clinical practice and self-management behaviors in this population. From a scientific perspective, little is known about nutrition and diet among older adults with type 1 diabetes, including baseline nutrition status, dietary intake and eating behaviors, and the impact of nutrition interventions on key clinical and patient-oriented outcomes. This likely reflects the population's recent emergence and unique considerations. Addressing these gaps is foundational to developing evidence-based nutrition practices and guidelines for older adults living with type 1 diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Considerations to Better Meet the Needs of People Living With Diabetes While in Prison or Detention.
- Author
-
West, Jennifer L., Ballard, Rebecca A., and May, John P.
- Subjects
TREATMENT of diabetes ,HEALTH services accessibility ,IMPRISONMENT ,PEOPLE with diabetes ,SELF-efficacy ,DISEASE management ,PRISON psychology ,MEDICAL needs assessment ,PSYCHOSOCIAL factors - Abstract
Diabetes care within prison walls offers challenges and opportunities for both health care providers and individuals living with diabetes. To meet the challenges, providers and patients work together to manage diabetes within the limitations imposed by imprisonment. Upon release, patients face new challenges, as they transition from incarceration into the community. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. The Effect of a Smartphone-Based, Patient-Centered Diabetes Care System in Patients With Type 2 Diabetes: A Randomized, Controlled Trial for 24 Weeks.
- Author
-
Eun Ky Kim, Soo Heon Kwak, Hye Seung Jung, Bo Kyung Koo, Min Kyong Moon, Soo Lim, Hak Chul Jang, Kyong Soo Park, Young Min Cho, Kim, Eun Ky, Kwak, Soo Heon, Jung, Hye Seung, Koo, Bo Kyung, Moon, Min Kyong, Lim, Soo, Jang, Hak Chul, Park, Kyong Soo, and Cho, Young Min
- Subjects
TYPE 2 diabetes treatment ,PATIENT-centered care ,RANDOMIZED controlled trials ,PATIENT self-monitoring ,BLOOD sugar monitoring ,HYPERGLYCEMIA treatment ,HYPOGLYCEMIA treatment ,INSULIN therapy ,HYPOGLYCEMIC agents ,BLOOD sugar ,CHOLESTEROL ,COMPARATIVE studies ,HYPERGLYCEMIA ,HYPOGLYCEMIA ,INSULIN ,RESEARCH methodology ,MEDICAL cooperation ,TYPE 2 diabetes ,RESEARCH ,STATISTICAL sampling ,TRIGLYCERIDES ,PILOT projects ,EVALUATION research ,BODY mass index - Abstract
Objective: This study evaluated the efficacy of a smartphone-based, patient-centered diabetes care system (mDiabetes) for type 2 diabetes that contains comprehensive modules for glucose monitoring, diet, physical activity, and a clinical decision support system.Research Design and Methods: We conducted a 24-week, multicenter, randomized controlled trial with adult patients with inadequately controlled type 2 diabetes. The patients were randomly assigned to the mDiabetes group or the paper logbook (pLogbook) group. The primary end point was the difference of the change in HbA1c from baseline between the two groups.Results: HbA1c reduction from baseline was greater in the mDiabetes group (-0.40 ± 0.09%, n = 90) than in the pLogbook group (-0.06 ± 0.10%, n = 82). The difference of adjusted mean changes was 0.35% (95% CI 0.14-0.55, P = 0.001). The proportion of patients whose HbA1c fell below 7.0% (53 mmol/mol) was 41.1% for the mDiabetes group and 20.7% for the pLogbook group (odds ratio [OR] 2.01, 95% CI 1.24-3.25, P = 0.003). The percentage of patients who attained HbA1c levels below 7.0% (53 mmol/mol) without hypoglycemia was 31.1% in the mDiabetes group and 17.1% in the pLogbook group (OR 1.82, 95% CI 1.03-3.21, P = 0.024). There was no difference in the event numbers of severe hyperglycemia and hypoglycemia between the two groups.Conclusions: The implementation of the mDiabetes for patients with inadequately controlled type 2 diabetes resulted in a significant reduction in HbA1c levels, with tolerable safety profiles. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
17. Relax & Refresh.
- Subjects
CALORIE ,ONIONS ,EDIBLE mushrooms ,COOKING - Abstract
Three calorie-smart recipes are presented including Strip Steak With Smothered Onions, Creamy Mushroom Soup and Raw Fig Bars.
- Published
- 2016
18. John E. Gerich: Father of Modern Physiology of Glucose Homeostasis, Counterregulation to Hypoglycemia, and Mechanistic Treatment of Diabetes.
- Author
-
Bolli, Geremia B.
- Subjects
GLUCAGON ,SOMATOTROPIN ,GLUCOSE ,INSULIN ,HYPOGLYCEMIA ,LIPID metabolism - Abstract
The author talks about John E. Gerich, his writings on glucagon and growth hormone responses in glucose with insulin induced hypoglycemia, working as a fellow in the lab of Rochester, performing clinical projects and studies. It talks about publications in PubMed that includes topics on glucose homeostasis, lipid metabolism, hypoglycemia, adipose tissue, liver and pancreas, writing about somatostatin hormones, relation of insulin dose with glucose and lipid metabolism and type 2 diabetes.
- Published
- 2018
- Full Text
- View/download PDF
19. Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management.
- Author
-
Du, Yang T., Rayner, Christopher K., Jones, Karen L., Talley, Nicholas J., and Horowitz, Michael
- Subjects
GASTROINTESTINAL diseases ,DIABETES complications ,GLYCEMIC control ,GLUCOSE in the body ,PATHOLOGICAL physiology ,DISEASE risk factors - Abstract
If you haven't measured something, you really don't know much about it.-Karl Pearson (attributed)Gastrointestinal (GI) symptoms represent an important and often unappreciated cause of morbidity in diabetes, although the significance of this burden across the spectrum of patients and the underlying pathophysiology, including the relationship of symptoms with glycemic control, remain poorly defined. The relevance of GI symptoms and the necessity for their accurate assessment have increased with the greater focus on the gut as a therapeutic target for glucose lowering. This review addresses the prevalence, assessment, pathogenesis, and management of GI symptoms in diabetes, beginning with broad principles and then focusing on specific segments of the GI tract. We initially performed a literature search of PubMed by using synonyms and combinations of the following search terms: "gastrointestinal symptoms", "diabetes", "prevalence", "pathogenesis", "diagnosis", and "management". We restricted the search results to English only. Review papers and meta-analyses are presented as the highest level of evidence where possible followed by randomized controlled trials, uncontrolled trials, retrospective and observational data, and expert opinion. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
20. Evaluating the Implementation of the EndoTool Glycemic Control Software System.
- Author
-
John, Samuel M., Waters, Kacie Lauren, and Jivani, Khatija
- Subjects
DIABETIC acidosis ,HYPERGLYCEMIA ,CHI-squared test ,COMPUTER software ,PEOPLE with diabetes ,INSULIN ,INSULIN pumps ,INTENSIVE care units ,MEDICAL technology ,T-test (Statistics) ,RETROSPECTIVE studies ,DATA analysis software ,GLYCEMIC control ,DIAGNOSIS - Abstract
Purpose. The purpose of this study was to compare achievement of glycemic control on insulin drips before and after the implementation of EndoTool, a glucose management software system used in a community hospital setting. Methods. A retrospective chart review was performed of patients on an insulin drip who were managed before and after implementation of the EndoTool software. Fifty patients were selected for each group. Statistical analyses were run to compare metrics gathered between groups. Results. Patients in the standard care group were on an insulin drip for an average of 23.9 hours compared to 20.9 hours in the EndoTool group (P = 0.38). Hypoglycemia occurred at an average rate of 0.036 events per patient in the standard group and 0.007 events per patient in the EndoTool group (P = 0.17). The average rate of hyperglycemia was 0.358 events per patient in the standard group and 0.283 events per patient in the EndoTool group (P = 0.25). The average time to achieve the blood glucose target was 2.78 and 3.67 hours in the standard and EndoTool groups, respectively (P = 0.27). Total patient values were within target range 45.2% of the time in the standard care group and 47.3% of the time in the EndoTool group (P = 0.71). Conclusion. Analysis of the implementation of EndoTool in the community hospital setting found no statistically significant differences between groups, although rates of hypo- and hyperglycemia showed a trend toward improved safety in the EndoTool group. These results could be attributed to the conservative parameters the hospital set in the initial phase of EndoTool implementation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
21. Philip Home—Insulin, Insight, and Internationalism.
- Author
-
Taylor, Roy
- Subjects
INSULIN pumps ,INSULIN ,INSULIN aspart ,INSULIN derivatives ,GLUCOSE clamp technique ,TYPE 1 diabetes - Abstract
The article reports that people have influenced the fields of insulin pharmacokinetics and international diabetes guidelines more than Philip Home. Topics include long career has been distinguished by involvement in many aspects of diabetes and a major international presence; and diamorphine injections and amphetamine tablets, and recalls the apparent lack of security.
- Published
- 2022
- Full Text
- View/download PDF
22. An Expanded Genome-Wide Association Study of Fructosamine Levels Identifies RCN3 as a Replicating Locus and Implicates FCGRT as the Effector Transcript.
- Author
-
Riveros-Mckay, Fernando, Roberts, David, Di Angelantonio, Emanuele, Yu, Bing, Soranzo, Nicole, Danesh, John, Selvin, Elizabeth, Butterworth, Adam S., and Barroso, Inês
- Subjects
GENOME-wide association studies ,GENETIC correlations ,LOCUS (Genetics) ,BLACK people ,GLYCOSYLATED hemoglobin ,RESEARCH ,SEQUENCE analysis ,GENETICS ,RESEARCH methodology ,CELL receptors ,METABOLISM ,GENETIC polymorphisms ,EVALUATION research ,TYPE 2 diabetes ,ATHEROSCLEROSIS ,COMPARATIVE studies ,CARBOHYDRATES ,GENES ,GENOMES ,RESEARCH funding ,CALCIUM-binding proteins ,HISTOCOMPATIBILITY antigens ,LONGITUDINAL method - Abstract
Fructosamine is a measure of short-term glycemic control, which has been suggested as a useful complement to glycated hemoglobin (HbA1c) for the diagnosis and monitoring of diabetes. To date, a single genome-wide association study (GWAS) including 8,951 U.S. White and 2,712 U.S. Black individuals without a diabetes diagnosis has been published. Results in Whites and Blacks yielded different association loci, near RCN3 and CNTN5, respectively. In this study, we performed a GWAS on 20,731 European-ancestry blood donors and meta-analyzed our results with previous data from U.S. White participants from the Atherosclerosis Risk in Communities (ARIC) study (Nmeta = 29,685). We identified a novel association near GCK (rs3757840, βmeta = 0.0062; minor allele frequency [MAF] = 0.49; Pmeta = 3.66 × 10-8) and confirmed the association near RCN3 (rs113886122, βmeta = 0.0134; MAF = 0.17; Pmeta = 5.71 × 10-18). Colocalization analysis with whole-blood expression quantitative trait loci data suggested FCGRT as the effector transcript at the RCN3 locus. We further showed that fructosamine has low heritability (h2 = 7.7%), has no significant genetic correlation with HbA1c and other glycemic traits in individuals without a diabetes diagnosis (P > 0.05), but has evidence of shared genetic etiology with some anthropometric traits (Bonferroni-corrected P < 0.0012). Our results broaden knowledge of the genetic architecture of fructosamine and prioritize FCGRT for downstream functional studies at the established RCN3 locus. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Pharmacological Activation of PDC Flux Reverses Lipid-Induced Inhibition of Insulin Action in Muscle During Recovery From Exercise.
- Author
-
Carl, Christian S., Jensen, Marie M., Sjøberg, Kim A., Constantin-Teodosiu, Dumitru, Hill, Ian R., Kjøbsted, Rasmus, Greenhaff, Paul L., Wojtaszewski, Jørgen F.P., Richter, Erik A., Fritzen, Andreas M., and Kiens, Bente
- Subjects
COOLDOWN ,PYRUVATE dehydrogenase complex ,INSULIN sensitivity ,TYPE 2 diabetes ,LEG muscles ,LEG exercises - Abstract
Insulin resistance is a risk factor for type 2 diabetes, and exercise can improve insulin sensitivity. However, following exercise, high circulating fatty acid (FA) levels might counteract this. We hypothesized that such inhibition would be reduced by forcibly increasing carbohydrate oxidation through pharmacological activation of the pyruvate dehydrogenase complex (PDC). Insulin-stimulated glucose uptake was examined with a crossover design in healthy young men (n = 8) in a previously exercised and a rested leg during a hyperinsulinemic-euglycemic clamp 5 h after one-legged exercise with 1) infusion of saline, 2) infusion of intralipid imitating circulating FA levels during recovery from whole-body exercise, and 3) infusion of intralipid + oral PDC activator, dichloroacetate (DCA). Intralipid infusion reduced insulin-stimulated glucose uptake by 19% in the previously exercised leg, which was not observed in the contralateral rested leg. Interestingly, this effect of intralipid in the exercised leg was abolished by DCA, which increased muscle PDC activity (130%) and flux (acetylcarnitine 130%) and decreased inhibitory phosphorylation of PDC on Ser
293 (∼40%) and Ser300 (∼80%). Novel insight is provided into the regulatory interaction between glucose and lipid metabolism during exercise recovery. Coupling exercise and PDC flux activation upregulated the capacity for both glucose transport (exercise) and oxidation (DCA), which seems necessary to fully stimulate insulin-stimulated glucose uptake during recovery. Article Highlights: Increased muscle insulin sensitivity following one-legged exercise is reduced by circulating fatty acid levels mimicking those observed in recovery from whole-body exercise. The fatty acid–induced inhibition of postexercise insulin action in muscle is alleviated by pharmacologically increasing PDC activation and flux to forcibly increase carbohydrate oxidation. Lipid infusion leading to fatty acid levels in the physiological range does not cause muscle insulin resistance in a rested leg. Muscle glucose uptake is linked to PDC activation state and flux during recovery from exercise in the presence of elevated plasma lipid availability. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
24. Hemoglobin A1c Trajectories During Pregnancy and Adverse Outcomes in Women With Type 2 Diabetes: A Danish National Population-Based Cohort Study.
- Author
-
Koefoed, Anna S., Knorr, Sine, Fuglsang, Jens, Leth-Møller, Magnus, Hulman, Adam, Jensen, Dorte M., Andersen, Lise Lotte T., Rosbach, A. Emilie, Damm, Peter, Mathiesen, Elisabeth R., Sørensen, Anne, Christensen, Trine T., McIntyre, H. David, Ovesen, Per, and Kampmann, Ulla
- Subjects
PREGNANCY outcomes ,TYPE 2 diabetes ,GLYCEMIC control ,COHORT analysis ,BIRTH weight - Abstract
OBJECTIVE To identify and characterize groups of pregnant women with type 2 diabetes with distinct hemoglobin A
1c (HbA1c ) trajectories across gestation and to examine the association with adverse obstetric and perinatal outcomes. RESEARCH DESIGN AND METHODS This was a retrospective Danish national cohort study including all singleton pregnancies in women with type 2 diabetes, giving birth to a liveborn infant, between 2004 and 2019. HbA1c trajectories were identified using latent class linear mixed-model analysis. Associations with adverse outcomes were examined with logistic regression models. RESULTS A total of 1,129 pregnancies were included. Three HbA1c trajectory groups were identified and named according to the glycemic control in early pregnancy (good, 59%; moderate, 32%; and poor, 9%). According to the model, all groups attained an estimated HbA1c <6.5% (48 mmol/mol) during pregnancy, with no differences between groups in the 3rd trimester. Women with poor glycemic control in early pregnancy had lower odds of having an infant with large-for-gestational-age (LGA) birth weight (adjusted odds ratio [aOR] 0.57, 95% CI 0.40-0.83), and higher odds of having an infant with small-for-gestational age (SGA) birth weight (aOR 2.49, 95% CI 2.00-3.10) and congenital malformation (CM) (aOR 4.60 95% CI 3.39-6.26) compared with women with good glycemic control. There was no evidence of a difference in odds of preeclampsia, preterm birth, and caesarean section between groups. CONCLUSIONS Women with poor glycemic control in early pregnancy have lower odds of having an infant with LGA birth weight, but higher odds of having an infant with SGA birth weight and CM. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
25. Association of Water Arsenic With Incident Diabetes in U.S. Adults: The Multi-Ethnic Study of Atherosclerosis and the Strong Heart Study.
- Author
-
Spaur, Maya, Galvez-Fernandez, Marta, Qixuan Chen, Lombard, Melissa A., Bostick, Benjamin C., Factor-Litvak, Pam, Fretts, Amanda M., Shea, Steven J., Navas-Acien, Ana, and Nigra, Anne E.
- Subjects
ARSENIC in water ,PROPORTIONAL hazards models ,TYPE 2 diabetes ,WELLS ,ATHEROSCLEROSIS - Abstract
OBJECTIVE We examined the association of arsenic in federally regulated community water systems (CWS) and unregulated private wells with type 2 diabetes (T2D) incidence in the Strong Heart Family Study (SHFS), a prospective study of American Indian communities, and the Multi-Ethnic Study of Atherosclerosis (MESA), a prospective study of racially and ethnically diverse urban U.S. communities. RESEARCH DESIGN AND METHODS We evaluated 1,791 participants from SHFS and 5,777 participants from MESA who had water arsenic estimates available and were free of T2D at baseline (2001-2003 and 2000-2002, respectively). Participants were followed for incident T2D until 2010 (SHFS cohort) or 2019 (MESA cohort). We used Cox proportional hazards mixed-effects models to account for clustering by family and residential zip code, with adjustment for sex, baseline age, BMI, smoking status, and education. RESULTS T2D incidence was 24.4 cases per 1,000 person-years (mean follow-up, 5.6 years) in SHFS and 11.2 per 1,000 person-years (mean follow-up, 14.0 years) in MESA. In a meta-analysis across the SHFS and MESA cohorts, the hazard ratio (95% CI) per doubling in CWS arsenic was 1.10 (1.02, 1.18). The corresponding hazard ratio was 1.09 (0.95, 1.26) in the SHFS group and 1.10 (1.01, 1.20) in the MESA group. The corresponding hazard ratio (95% CI) for arsenic in private wells and incident T2D in SHFS was 1.05 (0.95, 1.16). We observed statistical interaction and larger magnitude hazard ratios for participants with BMI <25 kg/m² and female participants. CONCLUSIONS Low to moderate water arsenic levels (<10 µg/L) were associated with T2D incidence in the SHFS and MESA cohorts. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Residual β-Cell Function Is Associated With Longer Time in Range in Individuals With Type 1 Diabetes.
- Author
-
Fuhri Snethlage, Coco M., McDonald, Timothy J., Oram, Richard D., de Groen, Pleun, Rampanelli, Elena, Schimmel, Alinda W. M., Holleman, Frits, Siegelaar, Sarah, Hoekstra, Joost, Brouwer, Catherine B., Knop, Filip K., Verchere, C. Bruce, van Raalte, Daniël H., Roep, Bart O., Nieuwdorp, Max, and Hanssen, Nordin M. J.
- Subjects
TYPE 1 diabetes ,CONTINUOUS glucose monitoring ,GLYCEMIC control ,INSULIN pumps ,INSULIN therapy - Abstract
OBJECTIVE Little is known about the influence of residual islet function on glycemic control in type 1 diabetes (T1D). We investigated the associations between residual β-cell function and metrics of continuous glucose monitoring (CGM) in individuals with T1D. RESEARCH DESIGN AND METHODS In this cross-sectional cohort comprising 489 individuals (64% female, age 41.0 ± 14.0 years), T1D duration was 15.0 (interquartile range [IQR] 6.0-29.0) years. Individuals had a time in range (TIR) of 66% (IQR 52-80%) and a urinary C-peptide-to-creatinine ratio (UCPCR) of 0.01 (IQR 0.00-0.41) nmol/mmol. To assess β-cell function, we measured UCPCR (detectable >0.01 nmol/mmol), and to assess α-cell function, fasting plasma glucagon/glucose ratios were measured. CGM was used to record TIR (3.9-10 mmol/L), time below range (TBR) (<3.9 mmol/L), time above range (TAR) (>10 mmol/L), and glucose coefficient of variance (CV). For CGM, 74.7% used FreeStyle Libre 2, 13.8% Medtronic Guardian, and 11.5% Dexcom G6 as their device. RESULTS The percentage of patients with T1D who had a detectable UCPCR was 49.4%. A higher UCPCR correlated with higher TIR (r = 0.330, P < 0.05), lower TBR (r = -0.237, P < 0.05), lower TAR (r = -0.302, P < 0.05), and lower glucose CV (r = -0.356, P < 0.05). A higher UCPCR correlated negatively with HbA1c levels (r = -0.183, P < 0.05) and total daily insulin dose (r = -0.183, P < 0.05). Glucagon/glucose ratios correlated with longer TIR (r = 0.234, P < 0.05). CONCLUSIONS Significantly longer TIR, shorter TBR and TAR, and lower CV were observed in individuals with greater UCPCR-assessed β-cell function. Therefore, better CGM-derived metrics in individuals with preserved β-cell function may be a contributor to a lower risk of developing long-term complications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Increasing Diabetic Foot Exam Rates in Primary Care Via a Toolkit for Registered Nurses.
- Author
-
Leonard, Valerie S.
- Subjects
NURSES ,INTERPROFESSIONAL relations ,MEDICAL quality control ,PRIMARY health care ,MEDICAL care ,DIABETIC foot ,ELECTRONIC health records ,QUALITY assurance ,MEDICAL screening ,DIABETES - Abstract
The article focuses on improving diabetic foot exam rates in primary care, highlighting a successful quality improvement initiative in a rural Alabama clinic. Topics include the clinic's adoption of a comprehensive diabetic foot screening toolkit, utilization of registered nurses' full scope of practice, and significant improvements in adherence to American Diabetes Association guidelines for foot exams, resulting in a 31 percent increase in completed exams compared to baseline data.
- Published
- 2024
- Full Text
- View/download PDF
28. Feasibility and Acceptability of an Agenda-Setting Kit in the Care of People With Type 2 Diabetes: The QBSAFE ASK Feasibility Study.
- Author
-
Haider, Shanzay, Gonzalez-Lopez, Carolina, Clark, Jennifer, Gravholt, Derek L., Breslin, Maggie, Boehmer, Kasey R., Hartasanchez, Sandra A., Sanchez, Brianna, Montori, Victor M., and Lipska, Kasia J.
- Subjects
HEALTH self-care ,PATIENT safety ,GLYCOSYLATED hemoglobin ,INTERPROFESSIONAL relations ,RESEARCH funding ,PILOT projects ,SYMPTOM burden ,PROBLEM solving ,PATIENT-centered care ,SURVEYS ,TYPE 2 diabetes ,QUALITY of life ,PHYSICIAN-patient relations ,PHYSICIANS ,EMPLOYEES' workload ,ADULTS - Abstract
This article reports on a study to assess the feasibility of research procedures and acceptability of QBSAFE, a set of conversation cards focused on quality of life, treatment burden, safety, and avoidance of future events in people with type 2 diabetes. The study enrolled 84 patients and 7 clinicians. Of the 58 patients who completed questionnaires, 64% agreed that the QBSAFE agenda-setting kit (ASK) helped them discuss their situation, 78% agreed that others could benefit from it, and 38% said they would use it again. Most clinicians felt confident responding to issues (in 89% of encounters) and said they would use the kit again (78%) and recommend it to colleagues (82%). The QBSAFE ASK can be feasibly implemented and holds promise in facilitating discussion and collaborative problem-solving. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Genetic Evidence for Distinct Biological Mechanisms That Link Adiposity to Type 2 Diabetes: Toward Precision Medicine.
- Author
-
Abraham, Angela, Cule, Madeleine, Thanaj, Marjola, Basty, Nicolas, Hashemloo, M. Amin, Sorokin, Elena P., Whitcher, Brandon, Burgess, Stephen, Bell, Jimmy D., Sattar, Naveed, Thomas, E. Louise, and Yaghootkar, Hanieh
- Subjects
TYPE 2 diabetes ,INDIVIDUALIZED medicine ,OBESITY ,HIGH cholesterol diet ,INSULIN sensitivity ,DIABETES complications - Abstract
We aimed to unravel the mechanisms connecting adiposity to type 2 diabetes. We used MR-Clust to cluster independent genetic variants associated with body fat percentage (388 variants) and BMI (540 variants) based on their impact on type 2 diabetes. We identified five clusters of adiposity-increasing alleles associated with higher type 2 diabetes risk (unfavorable adiposity) and three clusters associated with lower risk (favorable adiposity). We then characterized each cluster based on various biomarkers, metabolites, and MRI-based measures of fat distribution and muscle quality. Analyzing the metabolic signatures of these clusters revealed two primary mechanisms connecting higher adiposity to reduced type 2 diabetes risk. The first involves higher adiposity in subcutaneous tissues (abdomen and thigh), lower liver fat, improved insulin sensitivity, and decreased risk of cardiometabolic diseases and diabetes complications. The second mechanism is characterized by increased body size and enhanced muscle quality, with no impact on cardiometabolic outcomes. Furthermore, our findings unveil diverse mechanisms linking higher adiposity to higher disease risk, such as cholesterol pathways or inflammation. These results reinforce the existence of adiposity-related mechanisms that may act as protective factors against type 2 diabetes and its complications, especially when accompanied by reduced ectopic liver fat. Article Highlights: The relationship between excess adiposity and type 2 diabetes is complex. Can genetic subtypes of adiposity reveal distinct pathways linking adiposity with type 2 diabetes? Higher adiposity increases type 2 diabetes risk via different mechanisms (e.g., cholesterol pathways or inflammation) but decreases risk via other mechanisms (lower liver fat and improved insulin sensitivity, or increased body size and enhanced muscle quality). These insights could improve precision medicine for type 2 diabetes via treating adiposity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World Study.
- Author
-
Passanisi, Stefano, Salzano, Giuseppina, Bombaci, Bruno, Minuto, Nicola, Bassi, Marta, Bonfanti, Riccardo, Scialabba, Francesco, Mozzillo, Enza, Di Candia, Francesca, Monti, Sara, Graziani, Vanna, Maffeis, Claudio, Piona, Claudia Anita, Arnaldi, Claudia, Tosini, Davide, Felappi, Barbara, Roppolo, Rosalia, Zanfardino, Angela, Delvecchio, Maurizio, and Lo Presti, Donatella
- Subjects
TYPE 1 diabetes ,CLOSED loop systems ,GLYCOSYLATED hemoglobin ,TEENAGERS - Abstract
OBJECTIVE: To investigate glucose metrics and identify potential predictors of the achievement of glycemic outcomes in children and adolescents during their first 12 months of MiniMed 780G use. RESEARCH DESIGN AND METHODS: This multicenter, longitudinal, real-world study recruited 368 children and adolescents with type 1 diabetes (T1D) starting SmartGuard technology between June 2020 and June 2022. Ambulatory glucose profile data were collected during a 15-day run-in period (baseline), 2 weeks after automatic mode activation, and every 3 months. The influence of covariates on glycemic outcomes after 1 year of MiniMed 780G use was assessed. RESULTS: After 15 days of automatic mode use, all glucose metrics improved compared with baseline (P < 0.001), except for time below range (P = 0.113) and coefficient of variation (P = 0.330). After 1 year, time in range (TIR) remained significantly higher than at baseline (75.3% vs. 62.8%, P < 0.001). The mean glycated hemoglobin (HbA
1c ) over the study duration was lower than the previous year (6.9 ± 0.6% vs. 7.4 ± 0.9%, P < 0.001). Time spent in tight range (70–140 mg/dL) was 51.1%, and the glycemia risk index was 27.6. Higher TIR levels were associated with a reduced number of automatic correction boluses (P < 0.001), fewer SmartGuard exits (P = 0.021), and longer time in automatic mode (P = 0.030). Individuals with baseline HbA1c >8% showed more relevant improvement in TIR levels (from 54.3% to 72.3%). CONCLUSIONS: Our study highlights the sustained effectiveness of MiniMed 780G among youth with T1D. Findings suggest that even children and adolescents with low therapeutic engagement may benefit from SmartGuard technology. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
31. Proteomic Analyses in Diverse Populations Improved Risk Prediction and Identified New Drug Targets for Type 2 Diabetes.
- Author
-
Yao, Pang, Iona, Andri, Pozarickij, Alfred, Said, Saredo, Wright, Neil, Lin, Kuang, Millwood, Iona, Fry, Hannah, Kartsonaki, Christiana, Mazidi, Mohsen, Chen, Yiping, Bragg, Fiona, Liu, Bowen, Yang, Ling, Liu, Junxi, Avery, Daniel, Schmidt, Dan, Sun, Dianjianyi, Pei, Pei, and Lv, Jun
- Subjects
TYPE 2 diabetes ,DRUG target ,PROTEOMICS ,LOCUS (Genetics) ,GENOME-wide association studies ,FALSE memory syndrome - Abstract
OBJECTIVE: Integrated analyses of plasma proteomics and genetic data in prospective studies can help assess the causal relevance of proteins, improve risk prediction, and discover novel protein drug targets for type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: We measured plasma levels of 2,923 proteins using Olink Explore among ∼2,000 randomly selected participants from China Kadoorie Biobank (CKB) without prior diabetes at baseline. Cox regression assessed associations of individual protein with incident T2D (n = 92 cases). Proteomic-based risk models were developed with discrimination, calibration, reclassification assessed using area under the curve (AUC), calibration plots, and net reclassification index (NRI), respectively. Two-sample Mendelian randomization (MR) analyses using cis -protein quantitative trait loci identified in a genome-wide association study of CKB and UK Biobank for specific proteins were conducted to assess their causal relevance for T2D, along with colocalization analyses to examine shared causal variants between proteins and T2D. RESULTS: Overall, 33 proteins were significantly associated (false discovery rate <0.05) with risk of incident T2D, including IGFBP1, GHR, and amylase. The addition of these 33 proteins to a conventional risk prediction model improved AUC from 0.77 (0.73–0.82) to 0.88 (0.85–0.91) and NRI by 38%, with predicted risks well calibrated with observed risks. MR analyses provided support for the causal relevance for T2D of ENTR1, LPL, and PON3, with replication of ENTR1 and LPL in Europeans using different genetic instruments. Moreover, colocalization analyses showed strong evidence (pH4 > 0.6) of shared genetic variants of LPL and PON3 with T2D. CONCLUSIONS: Proteomic analyses in Chinese adults identified novel associations of multiple proteins with T2D with strong genetic evidence supporting their causal relevance and potential as novel drug targets for prevention and treatment of T2D. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. In Vivo Inhibition of Dipeptidyl Peptidase 4 Allows Measurement of GLP-1 Secretion in Mice.
- Author
-
Smits, Mark M., Galsgaard, Katrine D., Jepsen, Sara Lind, Albrechtsen, Nicolai Wewer, Hartmann, Bolette, and Holst, Jens J.
- Subjects
CD26 antigen ,GLUCAGON-like peptide 1 ,SECRETION ,GLUCOSE tolerance tests ,NEPRILYSIN - Abstract
Dipeptidyl peptidase 4 (DPP-4) and neprilysin (NEP) rapidly degrade glucagon-like peptide 1 (GLP-1) in mice. Commercially available sandwich ELISA kits may not accurately detect the degradation products, leading to potentially misleading results. We aimed to stabilize GLP-1 in mice, allowing reliable measurement with sensitive commercially available ELISA kits. Nonanesthetized male C57Bl/6JRj mice were subjected to an oral glucose tolerance test (OGTT; 2 g/kg glucose), and plasma total and intact GLP-1 were measured (Mercodia and Alpco ELISA kits, respectively). No GLP-1 increases were seen in samples taken beyond 15 min after the glucose load. Samples taken at 5 and 10 min after the OGTT showed a minor increase in total, but not intact, GLP-1. We then administered saline (control), or a DPP-4 inhibitor (valine pyrrolidide or sitagliptin) with or without an NEP-inhibitor (sacubitril), 30 min before the OGTT. In the inhibitor groups only, intact GLP-1 increased significantly during the OGTT. After injecting male C57Bl/6JRj mice with a known dose of GLP-1(7-36)NH
2 , peak GLP-1 levels were barely detectable after saline but were 5- to 10-fold higher during sitagliptin and the combination of sitagliptin/sacubitril. The half-life of the GLP-1 plasma disappearance increased up to sevenfold during inhibitor treatment. We conclude that reliable measurement of GLP-1 secretion is not possible in mice in vivo with commercially available sandwich ELISA kits, unless degradation is prevented by inhibition of DPP-4 and perhaps NEP. The described approach allows improved estimates of GLP-1 secretion for future studies, although it is a limitation that these inhibitors additionally influence levels of insulin and glucagon. Article Highlights: Reliable measurement of glucagon-like peptide 1 (GLP-1) in mice using commercially available ELISA kits is challenging because of rapid degradation by the enzymes dipeptidyl peptidase 4 and neprilysin. Total GLP-1 secretion can best be assessed early after giving a stimulus, yet at the risk of additionally measuring stress-induced GLP-1(1-36)NH2 . Intact GLP-1 can only be measured with concomitant in vivo inhibition of dipeptidyl peptidase 4 and perhaps neprilysin. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
33. Glucagon as the First Incretin: Objects (in the Rearview Mirror) Are Closer Than They Appear.
- Author
-
D'Alessio, David A. and Marks, Vincent
- Subjects
GASTRIC inhibitory polypeptide ,GLUCAGON ,REARVIEW mirrors ,GLUCAGON-like peptide 1 ,TYPE 1 diabetes - Abstract
The article discusses critical observations on metabolic physiology as of 2023. Topics covered include studies' suggestion that stimulatory actions of glucagon contribute to physiologic insulin secretion, and its promotion is independent of its effect to raise blood glucose. Also noted is the current active investigation of glucagon stimulation of B-cells.
- Published
- 2023
- Full Text
- View/download PDF
34. The Pathophysiology of Hyperglycemia in Older Adults: Clinical Considerations.
- Author
-
Lee, Pearl G. and Halter, Jeffrey B.
- Subjects
HYPERGLYCEMIA ,TYPE 2 diabetes ,DIABETES in old age ,OLDER people with diabetes ,COMORBIDITY - Abstract
Nearly a quarter of older adults in the U.S. have type 2 diabetes, and this population is continuing to increase with the aging of the population. Older adults are at high risk for the development of type 2 diabetes due to the combined effects of genetic, lifestyle, and aging influences. The usual defects contributing to type 2 diabetes are further complicated by the natural physiological changes associated with aging as well as the comorbidities and functional impairments that are often present in older people. This paper reviews the pathophysiology of type 2 diabetes among older adults and the implications for hyperglycemia management in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
35. Sorting Out the Receptor Isoforms Underlying Dopamine Inhibition of Insulin Secretion.
- Author
-
Kebede, Melkam A. and Piston, David W.
- Abstract
The article focuses on a study on the receptor isoforms in the negative regulation of insulin secretion by dopamine, which references a research paper by F. Uefune et al., published within the issue. It discusses the significant role of dopamine receptor in the dominant effect of dopamine on B-cells, and the use of overexpression systems to dissect the contributions of D1 nd D2 to dopamine signaling.
- Published
- 2022
- Full Text
- View/download PDF
36. Islets for Research: Nothing Is Perfect, but We Can Do Better.
- Author
-
Nano, Rita, Kerr-Conte, Julie A., Bosco, Domenico, Karlsson, Marie, Lavallard, Vanessa, Melzi, Raffaella, Gmyr, Valery, Mercalli, Alessia, Berney, Thierry, Pattou, François, Korsgren, Olle, and Piemonti, Lorenzo
- Subjects
ISLANDS of Langerhans ,ISLANDS of Langerhans transplantation ,COMPARATIVE studies ,DIABETES ,INSULIN ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,EVALUATION research - Abstract
In December 2018, Diabetes and Diabetologia began requiring authors of papers reporting data obtained from studies on human islets to report critical characteristics of the human islets used for research. The islet community was asked to provide feedback on it. Here is the contribution by the European Consortium for Islet Transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
37. Local Dialogues Between the Endocrine and Exocrine Cells in the Pancreas.
- Author
-
Rupnik, Marjan Slak and Hara, Manami
- Subjects
EXOCRINE pancreatic insufficiency ,PANCREAS ,SCIENTIFIC community ,ERYTHROCYTES ,BLOOD flow ,PANCREATIC diseases - Abstract
For many years, it has been taught in medical textbooks that the endocrine and exocrine parts of the pancreas have separate blood supplies that do not mix. Therefore, they have been studied by different scientific communities, and patients with pancreatic disorders are treated by physicians in different medical disciplines, where endocrine and exocrine function are the focus of endocrinologists and gastroenterologists, respectively. The conventional model that every islet in each pancreatic lobule receives a dedicated arterial blood supply was first proposed in 1932, and it has been inherited to date. Recently, in vivo intravital recording of red blood cell flow in mouse islets as well as in situ structural analysis of 3D pancreatic vasculature from hundreds of islets provided evidence for preferentially integrated pancreatic blood flow in six mammalian species. The majority of islets have no association with the arteriole, and there is bidirectional blood exchange between the two segments. Such vascularization may allow an entire downstream region of islets and acinar cells to be simultaneously exposed to a topologically and temporally specific plasma content, which could underlie an adaptive sensory function as well as common pathogeneses of both portions of the organ in pancreatic diseases, including diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. David M. Nathan: An Epic Investigator, An Epoch in Diabetes Care.
- Author
-
Wexler, Deborah J.
- Subjects
TYPE 1 diabetes ,DIABETES ,TYPE 2 diabetes ,HEMATOLOGISTS ,GLYCOSYLATED hemoglobin ,CONTINUOUS glucose monitoring ,DENTISTS - Abstract
The article focuses on celebrating the remarkable contributions of David M. Nathan to diabetes care and research. It highlights its modesty and significant impact on the field. It reports that despite Nathan's humility, developments in diabetes care through curiosity, collaboration, and leadership are shaping progress nationally and at Massachusetts General Hospital (MGH).
- Published
- 2024
- Full Text
- View/download PDF
39. Improved Glycemic Outcomes With Diabetes Technology Use Independent of Socioeconomic Status in Youth With Type 1 Diabetes.
- Author
-
Lomax, Kate E., Taplin, Craig E., Abraham, Mary B., Smith, Grant J., Haynes, Aveni, Zomer, Ella, Ellis, Katrina L., Clapin, Helen, Zoungas, Sophia, Jenkins, Alicia J., Harrington, Jennifer, de Bock, Martin I., Jones, Timothy W., Davis, Elizabeth A., Anderson, Kym, Andrikopoulos, Sof, Ambler, Geoff, Barrett, Helen, Batch, Jenny, and Bergman, Philip
- Subjects
TYPE 1 diabetes ,CONTINUOUS glucose monitoring ,SOCIOECONOMIC status ,INSULIN pumps ,DIABETES - Abstract
OBJECTIVE: Technology use in type 1 diabetes (T1D) is impacted by socioeconomic status (SES). This analysis explored relationships between SES, glycemic outcomes, and technology use. RESEARCH DESIGN AND METHODS: A cross-sectional analysis of HbA
1c data from 2,822 Australian youth with T1D was undertaken. Residential postcodes were used to assign SES based on the Index of Relative Socio-Economic Disadvantage (IRSD). Linear regression models were used to evaluate associations among IRSD quintile, HbA1c , and management regimen. RESULTS: Insulin pump therapy, continuous glucose monitoring, and their concurrent use were associated with lower mean HbA1c across all IRSD quintiles (P < 0.001). There was no interaction between technology use and IRSD quintile on HbA1c (P = 0.624), reflecting a similar association of lower HbA1c with technology use across all IRSD quintiles. CONCLUSIONS: Technology use was associated with lower HbA1c across all socioeconomic backgrounds. Socioeconomic disadvantage does not preclude glycemic benefits of diabetes technologies, highlighting the need to remove barriers to technology access. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
40. Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- Author
-
Cherrington, Andrea L., Tripputi, Mark T., Younes, Naji, Herman, William H., Katona, Aimee, Groessl, Erik J., Craig, Jacqueline, Gonzalez, Jeffrey S., Garg, Rajesh, Casula, Sabina, Kuo, Shihchen, Florez, Hermes J., Crandall, J.P., McKee, M.D., Behringer-Massera, S., Brown-Friday, J., Xhori, E., Ballentine-Cargill, K., Duran, S., and Estrella, H.
- Subjects
QUALITY of life ,COMPARATIVE method ,GLYCOSYLATED hemoglobin ,TYPE 2 diabetes ,DRUGS - Abstract
OBJECTIVE: Diabetes is associated with reduced health-related quality of life (HRQoL). Information on the relationship between HRQoL and glucose-lowering medications in recently diagnosed type 2 diabetes (T2D) is limited. We assessed changes in HRQoL in participants with T2D receiving metformin plus one of four glucose-lowering medications in Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). RESEARCH DESIGN AND METHODS: A total of 5,047 participants, baseline mean age 57 years, with <10 years T2D duration and glycated hemoglobin level 6.8–8.5% and taking metformin monotherapy, were randomly assigned to glargine, glimepiride, liraglutide, or sitagliptin. HRQoL was evaluated at baseline for 4,885 participants, and at years 1, 2, and 3, with use of the self-administered version of the Quality of Well-being Scale (QWB-SA) and SF-36 physical (PCS) and mental (MCS) component summary scales. Linear models were used to analyze changes in HRQoL over time in intention-to-treat analyses. RESULTS: None of the medications worsened HRQoL. There were no differences in QWB-SA or MCS by treatment group at any time point. PCS scores improved with liraglutide versus other groups at year 1 only. Greater weight loss during year 1 explained half the improvement in PCS scores with liraglutide versus glargine and glimepiride. Liraglutide participants in the upper tertile of baseline BMI showed the greatest improvement in PCS scores at year 1. CONCLUSIONS: Adding liraglutide to metformin in participants within 10 years of T2D diagnosis showed improvement in the SF-36 PCS in comparisons with the other medications at 1 year, which was no longer significant at years 2 and 3. Improvement was related to weight loss and baseline BMI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Longitudinal Changes in Sex Hormone Binding Globulin (SHBG) and Risk of Incident Diabetes: The Study of Women's Health Across the Nation (SWAN).
- Author
-
Hedderson, Monique M., Capra, Angela, Lee, Catherine, Habel, Laurel A., Lee, Jennifer, Gold, Ellen B., Badon, Sylvia E., Mitro, Susanna D., and El Khoudary, Samar R.
- Subjects
WOMEN'S health ,SEX hormones ,GLOBULINS ,DIABETES ,SURVIVAL analysis (Biometry) - Abstract
OBJECTIVE: To investigate the associations of longitudinal changes in sex hormone binding globulin (SHBG) and testosterone (T) over the menopause transition with the risk of diabetes. RESEARCH DESIGN AND METHODS: We followed 2,952 participants in the Study of Women's Health Across the Nation (SWAN) who were premenopausal or early perimenopausal and diabetes-free at baseline. SHBG,T, and estradiol (E2) levels were measured at up to 13 follow-up visits (over up to 17 years). We used complementary log-log–based discrete-time survival models anchored at baseline. RESULTS: Diabetes developed in 376 women. A 5-unit increase in time-varying SHBG was associated with a 10% reduced risk of diabetes (hazard ratio [HR] 0.91, 95% CI 0.87–0.95), adjusting for covariates, and baseline SHBG,T, and E2 levels. Time-varying T was not associated with diabetes risk. Compared with the lowest quartile for annual rate of change of SHBG since baseline (quartile 1 [Q1] −92.3 to −1.5 nmol/L), all other quartiles were associated with a decreased risk of diabetes adjusting for covariates and baseline SHBG; associations persisted after adjusting for rate of change of T and E2 (Q2 [> −1.5 to −0.2 nmol/L] HR 0.33, 95% CI 0.23–0.48; Q3 [> −0.2 to 1.3 nmol/L] HR 0.37, 95% CI 0.25–0.55; Q4 [>1.3 to 82.0 nmol/L] HR 0.43, 95% CI 0.30–0.63). CONCLUSIONS: Increasing levels of SHBG over the menopause transition were associated with a decreased risk of incident diabetes. Stable to increasing rates of change in SHBG were also independently associated with a decreased risk of diabetes compared with decreasing rates of change, suggesting SHBG may affect glucose through a mechanism beyond androgenicity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Patient Perspectives on the Benefits and Challenges of Diabetes and Digital Technology.
- Author
-
Edelman, Steve, Cheatham, Wayman W., Norton, Anna, and Close, Kelly L.
- Subjects
TREATMENT of diabetes ,BLOOD sugar monitors ,DIGITAL technology ,PATIENT education ,ATTITUDES toward illness ,DISEASE management ,PATIENT advocacy ,INDIVIDUALIZED medicine ,PATIENTS' attitudes ,HEALTH care teams ,DIABETES - Abstract
Diabetes technology continues to evolve, advancing with our understanding of human biology and improving our ability to treat people with diabetes. Diabetes devices are broadly classified into the following categories: glucose sensors, insulin delivery devices, and digital health care technology (i.e., software and mobile applications). When supported by education and individually tailored, technology can play a key role in optimizing outcomes. Digital devices assist in diabetes management by tracking meals, exercise, sleep, and glycemic measurements in real time, all of which can guide physicians and other clinicians in their decision-making. Here, as people with diabetes and patient advocates, as well as diabetes specialists, primary care providers, and diabetes care and education specialists, we present our perspectives on the advances, benefits, and challenges of diabetes technology in primary care practices. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Quantifying and Characterizing the Presence of Insulin Overbasalization in a Family Medicine Practice.
- Author
-
Stewart-Lynch, Autumn, Meyers, Rebekah, Sidig, Dina, McConville, Sea-oh, and Heiple, Lindsay
- Subjects
STATISTICAL correlation ,INSURANCE ,DISEASE management ,SCIENTIFIC observation ,FISHER exact test ,INSULIN ,SYMPTOMS ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,ODDS ratio ,TYPE 2 diabetes ,ELECTRONIC health records ,RESEARCH ,COMPARATIVE studies ,DATA analysis software ,CONFIDENCE intervals - Abstract
The American Diabetes Association advises clinicians of the potential for insulin overbasalization in the management of type 2 diabetes. Described as the titration of basal insulin beyond an appropriate dose, overbasalization increases risks for adverse effects such as hypoglycemia and weight gain without achieving the glycemic targets needed to optimally manage the disease. There is a need to determine the prevalence of and clinical factors that can lead to overbasalization. This study aimed to assess the prevalence of and characterize the patient variables associated with overbasalization in a family medicine practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Implementation of Diabetic Retinopathy Screening in Adult Patients With Type 2 Diabetes in a Primary Care Setting.
- Author
-
Clark, Katherine K., Gutierrez, Javier, Cody, Jessica R., and Padilla, Blanca Iris
- Subjects
HEALTH literacy ,HEALTH services accessibility ,HUMAN services programs ,INTERPROFESSIONAL relations ,VISION disorders ,DIABETIC retinopathy ,PRIMARY health care ,MOBILE hospitals ,STATISTICAL sampling ,TYPE 2 diabetes ,QUALITY of life ,MEDICAL screening ,QUALITY assurance ,HEALTH promotion ,EARLY diagnosis ,DISEASE complications ,ADULTS - Abstract
Diabetic retinopathy (DR) is a microvascular complication of type 2 diabetes and the leading cause of blindness globally. Although diabetes-related eye exams are widely recognized as an effective method for early detection of DR, which can help to prevent eventual vision loss, adherence to screening exams in the United States is suboptimal. This article describes a quality improvement project to increase DR screening rates and increase knowledge and awareness of DR in adults with type 2 diabetes in a primary care setting using mobile DR screening units. This project addressed gaps of care and demonstrated that primary care settings can increase access to DR screening through a patient-centered process and thereby help to prevent irreversible outcomes of DR and improve quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Impact of the COVID-19 Pandemic on Medical Expenditures Among Medicare Fee-for-Service Beneficiaries Aged ≥67 Years With Diabetes.
- Author
-
Wang, Yu, Zhang, Ping, Zhou, Xilin, Rolka, Deborah, and Imperatore, Giuseppina
- Subjects
COVID-19 pandemic ,MEDICARE beneficiaries ,DIABETES ,PER capita ,PANDEMICS - Abstract
OBJECTIVE: To compare total and out-of-pocket (OOP) medical expenditures between pre–COVID-19 (March 2019 to February 2020) and COVID-19 (March 2020 to February 2022) periods among Medicare beneficiaries with diabetes. RESEARCH DESIGN AND METHODS: Data were from 100% Medicare fee-for-service claims. Diabetes was identified using ICD-10 codes. We calculated quarterly total and OOP medical expenditures at the population and per capita level in total and by service type. Per capita expenditures were calculated by dividing the population expenditure by the number of beneficiaries with diabetes in the same quarter. Changes in expenditures were calculated as the differences in the same quarters between the prepandemic and pandemic years. RESULTS: Population total expenditure fell to $33.6 billion in the 1st quarter of the pandemic from $41.7 billion in the same prepandemic quarter; it then bounced back to $36.8 billion by the 4th quarter of the 2nd pandemic year. The per capita total expenditure fell to $5,356 in the 1st quarter of the pandemic from $6,500 in the same prepandemic quarter. It then increased to $6,096 by the 4th quarter of the 2nd pandemic year, surpassing the same quarter in the prepandemic year ($5,982). Both population and per capita OOP expenditures during the pandemic period were lower than the prepandemic period. Changes in per capita expenditure between the pre–COVID-19 and COVID-19 periods by service type varied. CONCLUSIONS: COVID-19 had a significant impact on both total and per capita medical expenditures among Medicare beneficiaries with diabetes. The COVID-19 pandemic was associated with lower OOP expenditures. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Modifiable Lifestyle Factors, Genetic Risk, and Incident Peripheral Artery Disease Among Individuals With Type 2 Diabetes: A Prospective Study.
- Author
-
Zhu, Kai, Qian, Frank, Lu, Qi, Li, Rui, Qiu, Zixin, Li, Lin, Li, Ruyi, Yu, Hancheng, Deng, Yulei, Yang, Kun, Pan, An, and Liu, Gang
- Subjects
PERIPHERAL vascular diseases ,TYPE 2 diabetes ,GENETIC risk score ,SLEEP duration ,SINGLE nucleotide polymorphisms - Abstract
OBJECTIVE: To prospectively evaluate the association between modifiable lifestyle factors and peripheral artery disease (PAD) among individuals with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: We included 14,543 individuals with T2D from the UK Biobank. We defined a weighted healthy lifestyle score using nonsmoking, regular physical activity, high-quality diet, moderate alcohol consumption, optimal waist-to-hip ratio, and adequate sleep duration, and categorized into unfavorable, intermediate, and favorable lifestyles. We created a genetic risk score (GRS) using 19 single nucleotide polymorphisms previously found to be associated with PAD. We modeled the association between lifestyle score and PAD, overall and stratified by PAD genetic susceptibility. RESULTS: After a median 13.5 years of follow-up, 628 incident cases of PAD were documented. A linear inverse association between the weighted lifestyle score and PAD was observed, with a hazard ratio (HR) (95% CI) of 0.27 (0.19, 0.38) for favorable compared with unfavorable lifestyle (P
trend < 0.0001). An estimated 58.3% (45.0%, 69.1%) of PAD in this population could be potentially avoidable if all participants attained a favorable lifestyle. Moreover, the PAD GRS was associated with increased PAD risk (HR [95% CI] per SD increment: 1.13 [1.03, 1.23]). A favorable lifestyle was able to partially mitigate the excess risk of PAD associated with higher GRS, albeit as a nonsignificant interaction. Several biomarkers in the lipid metabolism, hepatic/renal function, and systemic inflammation pathways collectively explained 13.3% (8.5%, 20.1%) of the association between weighted lifestyle score and PAD. CONCLUSIONS: A favorable lifestyle was associated with lower risk of PAD among individuals with T2D, independent of genetic predisposition to PAD. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
47. Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?
- Author
-
Buse, John B., D'Alessio, David A., and Riddle, Matthew C.
- Subjects
TYPE 2 diabetes treatment ,DIABETES in youth ,AGE factors in disease ,TYPE 1 diabetes ,TYPE 2 diabetes - Abstract
An introduction is presented for a series of studies and research papers on the treatment of youth-onset type two diabetes.
- Published
- 2018
- Full Text
- View/download PDF
48. Statement of Retraction. Iria Nieto-Vázquez, Sonia Fernández-Veledo, Cristina de Alvaro, Cristina M. Rondinone, Angela M. Valverde, and Margarita Lorenzo. Protein-Tyrosine Phosphatase 1B-Deficient Myocytes Show Increased Insulin Sensitivity and Protection Against Tumor Necrosis Factor-α-Induced Insulin Resistance. Diabetes 2007;56:404-413. https://doi.org/10.2337/db06-0989.
- Author
-
American Diabetes Association
- Subjects
PROTEIN-tyrosine phosphatase ,INSULIN resistance ,MUSCLE cells ,MARGARITAS - Abstract
The article discusses that the learning that certain representative immunoblot images in the above-cited paper may have been duplicated, authors Iria Nieto-Vázquez, Sonia Fernández-Veledo, Cristina M. Rondinone, and Ángela M. Valverde have decided to voluntarily retract the article.
- Published
- 2020
- Full Text
- View/download PDF
49. Living Within the Redlines: How Structural Racism and Redlining Shape Diabetes Disparities.
- Author
-
Ogungbe, Oluwabunmi, Yeh, Hsin-Chieh, and Cooper, Lisa A.
- Subjects
INSTITUTIONAL racism ,DIABETES ,RESIDENTIAL segregation ,MEDICAL personnel ,DISCRIMINATION in medical care - Abstract
This article, published in Diabetes Care, explores the relationship between structural racism and diabetes disparities in the United States. The study finds that racial and ethnic minority groups, including American Indian or Alaska Native, Black, Hispanic, and Asian adults, bear a disproportionate burden of diabetes compared to White adults. The authors argue that structural determinants of health, such as residential segregation and unequal access to healthcare and education, contribute to these disparities. The study also uses historic redlining as a proxy for structural racism and finds significant direct and indirect relationships between redlining and diabetes prevalence. The authors emphasize the need for further research and interventions to address the root causes of health disparities and promote health equity. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
50. 13. Older Adults: Standards of Care in Diabetes—2024.
- Author
-
American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., Aleppo, Grazia, Bannuru, Raveendhara R., Bruemmer, Dennis, Collins, Billy S., Ekhlaspour, Laya, Hilliard, Marisa E., Johnson, Eric L., Khunti, Kamlesh, Lingvay, Ildiko, Matfin, Glenn, McCoy, Rozalina G., Perry, Mary Lou, Pilla, Scott J., Polsky, Sarit, Prahalad, Priya, Pratley, Richard E., Segal, Alissa R., and Seley, Jane Jeffrie
- Subjects
OLDER people ,DIABETES ,PROFESSIONAL practice - Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.